US-based MediBalloon, Inc. has announced a partnership with Medeon Biodesign, Inc., a Taiwan publicly traded medical device company with operations in Taipei, Taiwan and Sunnyvale, California, to expand the US operations and footprint in Asia.

The new manufacturing organization established in Taiwan will be called Medeologix and will be in full operation in 2022 to not only serve the global market, but also provide customers the one-stop-shop service from prototyping to mass production of medical devices.

MediBalloon, with over 25 years of medical device industry experience, is specialized in specialty medical balloons across a wide range of clinical applications including cardiovascular, neurovascular, structural heart, peripheral, general surgery and urology. 

Anant Hegde, the founder and CTO of MediBalloon, and board member of Medeologix stated, "We provide short turnaround time during the design and development phase, and now we will be equipped with a state-of-the-art facility and multiple production lines, which significantly boosts our capacity to meet the growing demand of mass production for our global customers."